Barbarian At The Gate: United Therapeutics (UTHR)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified United Therapeutics ( UTHR) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate. In addition to specific proprietary factors, Trade-Ideas identified United Therapeutics as such a stock due to the following factors:

  • UTHR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $44.7 million.
  • UTHR has traded 132,405 shares today.
  • UTHR traded in a range 313.8% of the normal price range with a price range of $6.02.
  • UTHR traded above its daily resistance level (quality: 29 days, meaning that the stock is crossing a resistance level set by the last 29 calendar days. The resistance price is defined by the Price - $0.01 at the time of the signal).

Stocks matching the 'Barbarian at the Gate' criteria are worthwhile stocks to watch for a variety of factors including historical back testing and volatility. Trade-Ideas targets these opportunities because the stock is exhibiting an unusual behavior while displaying positive price action. In this case, the stock crossed an important inflection point; namely, 'resistance' while at the same time the range of the stock's movement in price is more than twice its normal size. This large range foreshadows a possible continuation as the stock moves higher.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in UTHR with the Ticky from Trade-Ideas. See the FREE profile for UTHR NOW at Trade-Ideas

If you liked this article you might like

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

United Therapeutics, DOJ in Possible Settlement Over Drug Contributions

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Biotech Movers: Novocure, United Therapeutics, Kite Pharma

United Therapeutics Stock Slumping on Credit Suisse Rating